Zimmer Biomet stock rating cut to neutral by BTIG on growth concerns

robot
Abstract generation in progress

BTIG has downgraded Zimmer Biomet (NYSE:ZBH) from Buy to Neutral and removed its $112 price target, citing limited prospects for share returns due to challenging growth in fiscal 2025 and an anticipated modest guidance for 2026. Despite exceeding Q4 earnings expectations and strategic efforts to strengthen its product lineup, the firm believes that new products and autonomous robotics will not significantly drive outperformance in the near term. The stock is currently trading near its 52-week low, reflecting investor concerns.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin